Similar articles

• [Phosphodiesterase inhibition as a new positive-inotropic principle].

  Hartmann A, Saeed M, Sütsch G, Bing RJ. Hartmann A, et al. Dtsch Med Wochenschr. 1986 Dec 19;111(51-52):1971-7. doi: 10.1055/s-2008-1068746. Dtsch Med Wochenschr. 1986. PMID: 3539571 Review. German. No abstract available.
• [Positive inotropic agents in heart failure. Clinico-pharmacological evidence for medical practice].

  Rohde LE, Ribeiro JP. Rohde LE, et al. Arq Bras Cardiol. 1994 Dec;63(6):537-42. Arq Bras Cardiol. 1994. PMID: 7605243 Review. Portuguese. No abstract available.
• Review: therapeutic concepts of congestive heart failure.

  Haustein KO. Haustein KO. Int J Clin Pharmacol Ther Toxicol. 1990 Jul;28(7):273-81. Int J Clin Pharmacol Ther Toxicol. 1990. PMID: 1974888 Review.
• [Positive inotropic substances--therapeutic perspectives].

  Erdmann E, Böhm M. Erdmann E, et al. Z Kardiol. 1991;80 Suppl 8:57-62. Z Kardiol. 1991. PMID: 1796636 Review. German.
• [Positive inotropic substances in therapy of heart failure: digitalis, catecholamines, phosphodiesterase inhibitors].

  Stefenelli T. Stefenelli T. Acta Med Austriaca. 1991;18(4):81-5. Acta Med Austriaca. 1991. PMID: 1763582 Review. German.